Studies of White Blood Cells Derived From HHT Patients
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to take blood samples from patients with HHT, and culture white blood cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in media prompting different types of differentiation, or infection of cell lines with Epstein Barr virus to provide cell lines which can be repeatedly studied. It is anticipated that DNA, mRNA and proteins will be extracted from these cells for study of white cell responses and association with expression levels of endoglin and ALK-1 We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.
| Condition |
|---|
|
Telangiectasia, Hereditary Hemorrhagic |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Studies of White Blood Cells Derived From HHT Patients |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with HHT, and family members
Exclusion Criteria:
- Unable to provide informed consent
Contacts and Locations| Contact: Claire L Shovlin | 0208 383 1000 | c.shovlin@imperial.ac.uk |
| United Kingdom | |
| Imperial College Hammersmith Campus | Recruiting |
| London, United Kingdom, W12 0NN | |
| Contact: Claire L Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk | |
| Principal Investigator: Claire L Shovlin | |
| Principal Investigator: | Claire L Shovlin | Imperial College London |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00230633 History of Changes |
| Other Study ID Numbers: | IC/CLS3 |
| Study First Received: | September 29, 2005 |
| Last Updated: | August 12, 2008 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Telangiectasia, Hereditary Hemorrhagic Telangiectasis Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Hemorrhagic Disorders Hematologic Diseases Vascular Malformations Cardiovascular Abnormalities Congenital Abnormalities |
ClinicalTrials.gov processed this record on May 16, 2013